Human serum stimulates endothelin-1 synthesis more potently than prostacyclin production by cultured vascular endothelial cells. 1991

A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
Children's Hospital, University of Helsinki, Finland.

Human serum stimulated the synthesis of a vasoconstrictive peptide, endothelin-1 (ET-1), and a vasodilatory prostanoid, prostacyclin (PGI2), by cultured human umbilical vein endothelial cells in a concentration- and time-dependent manner. Incubation in 20% concentration of the serum for 24 h stimulated ET-1 synthesis almost six-fold while PGI2 production increased two-fold. In addition, a tumor-promoting phorbol ester, phorbol 12-myristate 13-acetate (PMA), inhibited the serum-induced ET-1 production and stimulated PGI2 synthesis in a concentration- and time-dependent manner. Our results suggest that human serum derived factor(s) stimulate the production of vasoconstrictive ET-1 more potently than the synthesis of vasodilatory PGI2 by human vascular endothelial cells and that the production of these agents is differentially regulated by PMA.

UI MeSH Term Description Entries
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001769 Blood The body fluid that circulates in the vascular system (BLOOD VESSELS). Whole blood includes PLASMA and BLOOD CELLS.
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013755 Tetradecanoylphorbol Acetate A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA. Phorbol Myristate Acetate,12-Myristoyl-13-acetylphorbol,12-O-Tetradecanoyl Phorbol 13-Acetate,Tetradecanoylphorbol Acetate, 4a alpha-Isomer,12 Myristoyl 13 acetylphorbol,12 O Tetradecanoyl Phorbol 13 Acetate,13-Acetate, 12-O-Tetradecanoyl Phorbol,Acetate, Phorbol Myristate,Acetate, Tetradecanoylphorbol,Myristate Acetate, Phorbol,Phorbol 13-Acetate, 12-O-Tetradecanoyl,Tetradecanoylphorbol Acetate, 4a alpha Isomer
D016232 Endothelins 21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides. Endothelium-Derived Vasoconstrictor Factors,Endothelin,Vasoconstrictor Factors, Endothelium-Derived

Related Publications

A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
May 1989, Biochemical and biophysical research communications,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
March 1996, Thrombosis research,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
March 1991, The Journal of clinical endocrinology and metabolism,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
April 1988, Thrombosis and haemostasis,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
January 1991, Journal of cardiovascular pharmacology,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
June 1995, The Journal of clinical endocrinology and metabolism,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
March 1981, The Journal of clinical investigation,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
January 1989, Advances in prostaglandin, thromboxane, and leukotriene research,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
January 1993, Life sciences,
A Ristimäki, and R Renkonen, and O Saijonmaa, and O Ylikorkala, and L Viinikka
December 1982, Diabete & metabolisme,
Copied contents to your clipboard!